Skip to main content
Compugen Ltd. logo

Compugen Ltd. — Investor Relations & Filings

Ticker · CGEN ISIN · IL0010852080 TA Professional, scientific and technical activities
Open in API
Filings indexed 1,165 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country IL Israel
Listing TA CGEN

About Compugen Ltd.

https://www.cgen.com/

Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Regulatory Filings
2026-05-18 Hebrew (modern)
Other Report or Announcement
Report Publication Announcement Classification · 90% confidence The document is a short announcement filed via the Tel Aviv Stock Exchange’s MAGNA system stating the corporation has scheduled publication and attached a Form F-3 report. It does not contain the actual financial report content itself but simply notifies investors of its publication. Per the “menu vs meal” rule, this qualifies as a Report Publication Announcement (RPA).
2026-05-18 English
Reports First Quarter 2026 Results
Earnings Release Classification · 83% confidence The document is a Form 6-K furnishing the company’s press release reporting its first quarter 2026 results, including financial highlights and condensed financial tables. This is the company’s initial announcement of its quarterly financial results rather than a full annual report or comprehensive interim report. Therefore, it fits the definition of an Earnings Release (ER). Q1 2026
2026-05-18 English
Reports First Quarter 2026 Results
Report Publication Announcement Classification · 91% confidence The document is an immediate report notice under Israeli Securities Regulations stating that the Q1 2026 results report is attached as a PDF. It does not contain any substantive financial data itself, but simply announces and attaches a separate report. Under the “menu vs. meal” rule, this is a report publication announcement, not the report itself.
2026-05-18 English
To Participate in 2026 Stifel Virtual Targeted Oncology Forum
Regulatory Filings Classification · 10% confidence The document is a corporate press release announcing that Compugen management will present at the 2026 Stifel Virtual Targeted Oncology Forum, providing event details and webcast information. It does not contain financial results, substantive financial statements, or detailed investor slides, nor does it constitute a formal report or regulatory filing beyond a general announcement. It is therefore best classified as a general regulatory/press announcement under the fallback category “Regulatory Filings (RNS).”
2026-05-12 English
To Participate in 2026 Stifel Virtual Targeted Oncology Forum
Report Publication Announcement Classification · 82% confidence The document is a brief ISA/TASE filing announcing that a report (the oncology forum presentation) is attached and scheduled for publication. It contains no substantive report content itself, merely a notice of publication and reference to an attached PDF. Under the “menu vs meal” rule, this is an announcement of a report, not the report itself.
2026-05-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.